This Biotech ETF Is a Catalyst-Rich Story

Biotechnology stocks and the related ETFs bounced back in significant fashion last year. There's been some cooling of that trend to start 2026, but that could be just the opportunity some investors have been waiting for to get involved with ETFs such as the ALPS Medical Breakthroughs ETF (SBIO).

ETF Trends • Feb 20, 2026

Biotech M&A Wave Positions SBIO for Growth

The biotech M&A market is heating up as pharmaceutical companies confront a looming patent cliff that will strip $200 billion to $250 billion in branded medicine sales by 2032, according to an ING report published in January.

ETF Trends • Jan 29, 2026

Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?

Wall Street put up a modest show in the final quarter of 2025, with the S&P 500 advancing only 1.9%, the Dow Jones gaining 3.3% and the Nasdaq Composite adding about 2.1%. The small-cap index Russell 2000 added 1.6% during that period.

Zacks Investment Research • Jan 6, 2026

ALPS ETFs in Biotech and Commodities Lead 2025 Gains

Biotech and natural resources funds led the ALPS ETFs lineup in 2025, with both strategies delivering returns above 45%, according to ETF Database. The ALPS Medical Breakthroughs ETF (SBIO) gained just over 57% through December 23, topping all ALPS products for the year, according to ETF Database.

ETF Trends • Dec 26, 2025

Biotech ETF SBIO Hovers Near Peak on Rally

The ALPS Medical Breakthroughs ETF (SBIO) is trading close to its 52-week high of $51.87 after surging 10.51% in November, powered by a wave of positive clinical trial data and renewed merger activity in small- and midcap biotech companies, according to research from SS&C ALPS Advisors. The biotech ETF outpaced the Nasdaq Biotechnology Index's 8.

ETF Trends • Dec 15, 2025

SBIO: A Shock Biotech Winner In 2025

The ALPS Medical Breakthroughs ETF has staged a remarkable comeback, outperforming despite a challenging macro backdrop and small-cap weakness. SBIO benefited from a rebound in FDA drug approvals, positive clinical news, and increased M&A activity as large pharma seeks pipeline replenishment. Risks remain high for SBIO, including sector volatility, unprofitability, sensitivity to interest rates, and potential regulatory or political headwinds.

Seeking Alpha • Nov 28, 2025

Sabio Holdings Inc. (SBIO:CA) Q3 2025 Earnings Call Transcript

Sabio Holdings Inc. ( SBIO:CA ) Q3 2025 Earnings Call November 25, 2025 10:00 AM EST Company Participants Aziz Rahimtoola - Co-Founder, CEO & Chairman Sajid Premji - Chief Financial Officer Conference Call Participants Gabriel Leung - Beacon Securities Limited, Research Division Daniel Rosenberg - Paradigm Capital Inc., Research Division Nicholas Cortellucci - Atrium Research Corporation Presentation Operator Good morning, everyone, and welcome to Sabio Holdings Third Quarter 2025 Earnings Call. The financial statements and management discussion and analysis are available on SEDAR+.

Seeking Alpha • Nov 25, 2025

Biotech Consolidation Could Perk Up, Lift This ETF

Regarding the healthcare sector again disappointing investors in 2025 — the largest ETF addressing the group is up just 11.39% — there are pockets of strength. Those include biotech stocks and the related ETFs.

ETF Trends • Nov 19, 2025

Investing In Health Stocks - How Policy Clarity Is Opening Doors

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Seeking Alpha • Nov 11, 2025

3 Stocks Driving Biotech ETF SBIO's Appeal

In the shifting landscape of ETFs, many funds claim to offer exposure to innovation. Technology plays a key role as a growth industry and a driver for performance across the economy overall, as well.

ETF Trends • Sep 11, 2025